We here show that FBXW7 deficiency, one of the most frequent events in human cancer (Lawrence et al, 2013), increases the resistance to the vast majority of available anticancer therapies, likely contributing to the bad prognosis that is associated with FBXW7 mutations (Kandoth et al, 2013). This evidence concerns the gene FBXW7 and cancer.